Research Study Investigating How Well Semaglutide Works in People With Type 2 Diabetes Suffering From Overweight or Obesity

NCT03552757 on ClinicalTrials.gov · last registry update 2021-11-09

An unusually large phase 3: 1,210 participants, more than double the 424 typical for the stage. The sponsor logged completion for 24 March 2020. Primary outcome, as filed: Change in Body Weight (%) - Semaglutide 2.4 mg Versus Placebo. semaglutide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Novo Nordisk A/S
Sponsor type: Industry
Enrollment: 1,210
Started: 2018-06-04
Primary completion: 2020-03-24 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in Body Weight (%) - Semaglutide 2.4 mg Versus Placebo

Conditions studied

Obesity · Overweight

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.